Access cutting-edge immune thrombocytopenia treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access immune thrombocytopenia specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related immune thrombocytopenia treatment provided free
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active in
Sponsor: Takeda
Check if you qualify for this immune thrombocytopenia clinical trial in Washington Dc, DC
If you're searching for immune thrombocytopenia treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.